Literature DB >> 16002026

Drug use practices among MDMA/ecstasy users in Ohio: a latent class analysis.

Robert G Carlson1, Jichuan Wang, Russel S Falck, Harvey A Siegal.   

Abstract

This study describes the drug use practices among 402 recent MDMA (3,4-methelyenedioxymethamphetamine) users recruited in Ohio using respondent-driven sampling. About 64% of the participants were men, 81.6% were white, and the mean age was 20.9 years. Latent class analysis was used to identify subgroups of MDMA users. Use of cocaine, opioids, amphetamines, tranquilizers, inhalants, marijuana, and hallucinogens during the previous 6 months, and days of "drunkenness" in the past 30, were used for classification. A three-class model was preferable and reflected "Limited range," "Moderate range," and "Wide range" drug use patterns. For example, the conditional probability of using opioids during the previous 6 months was .07 in Class 1, .59 in Class 2, and .88 in Class 3. Other substances followed similar patterns. Predictors of class membership were examined in a multinomial logit model in which the "Limited range" Class was treated as the reference group. Participants who were white, younger, and who reported more than 10 occasions of MDMA use were more likely to be in the "Wide range" drug use Class. Latent class analysis is a useful method to help describe and understand variability in polydrug use patterns.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16002026     DOI: 10.1016/j.drugalcdep.2005.01.011

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


  33 in total

1.  Distinguishing subpopulations of marijuana users with latent profile analysis.

Authors:  Matthew R Pearson; Adrian J Bravo; Bradley T Conner
Journal:  Drug Alcohol Depend       Date:  2016-11-23       Impact factor: 4.492

2.  Poly-Drug Use among Ecstasy Users: Separate, Synergistic, and Indiscriminate Patterns.

Authors:  M Boeri; C Sterk; M Bahora; K Elifson
Journal:  J Drug Issues       Date:  2008-04

3.  Heterogeneity in the Co-occurrence of Substance Use and Posttraumatic Stress Disorder: A Latent Class Analysis Approach.

Authors:  Ateka A Contractor; Nicole H Weiss; Katherine L Dixon-Gordon; Heidemarie Blumenthal
Journal:  J Dual Diagn       Date:  2019-03-06

4.  Locally dependent latent class models with covariates: an application to under-age drinking in the USA.

Authors:  Beth A Reboussin; Edward H Ip; Mark Wolfson
Journal:  J R Stat Soc Ser A Stat Soc       Date:  2008-10       Impact factor: 2.483

5.  Latent class analysis of non-opioid dependent illegal pharmaceutical opioid users in Ohio.

Authors:  Robert G Carlson; Ramzi W Nahhas; Raminta Daniulaityte; Silvia S Martins; Linna Li; Russel Falck
Journal:  Drug Alcohol Depend       Date:  2013-10-23       Impact factor: 4.492

6.  Risk factor profiles among intravenous drug using young adults: a latent class analysis (LCA) approach.

Authors:  Sigrid James; Edward S McField; Susanne B Montgomery
Journal:  Addict Behav       Date:  2012-09-23       Impact factor: 3.913

7.  A latent class analysis of alcohol and drug use immediately before or during sex among women.

Authors:  Grace L Reynolds; Dennis G Fisher
Journal:  Am J Drug Alcohol Abuse       Date:  2018-10-25       Impact factor: 3.829

8.  Tri-city study of Ecstasy use problems: a latent class analysis.

Authors:  Lawrence M Scheier; Arbi Ben Abdallah; James A Inciardi; Jan Copeland; Linda B Cottler
Journal:  Drug Alcohol Depend       Date:  2008-07-31       Impact factor: 4.492

9.  Modifiable risk factors of ecstasy use: risk perception, current dependence, perceived control, and depression.

Authors:  Kit Sang Leung; Arbi Ben Abdallah; Jan Copeland; Linda B Cottler
Journal:  Addict Behav       Date:  2009-10-18       Impact factor: 3.913

10.  Typology of club drug use among young adults recruited using time-space sampling.

Authors:  Danielle E Ramo; Christian Grov; Kevin Delucchi; Brian C Kelly; Jeffrey T Parsons
Journal:  Drug Alcohol Depend       Date:  2009-11-24       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.